Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 2
Submit an article Journal homepage
292
Views
10
CrossRef citations to date
0
Altmetric
Perspective

Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries

András InotaiSyreon Research Institute, Budapest, Hungary;Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, HungaryCorrespondence[email protected]
View further author information
,
Tamás ÁghSyreon Research Institute, Budapest, HungaryView further author information
,
Alexei Willem KarpenkoErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The NetherlandsView further author information
,
Antal ZemplényiSyreon Research Institute, Budapest, Hungary;Department of Pharmacoeconomics, University of Pécs, Pécs, HungaryView further author information
&
Zoltán KalóSyreon Research Institute, Budapest, Hungary;Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, HungaryORCID Iconhttp://orcid.org/0000-0001-7762-2607View further author information
ORCID Icon
Pages 105-113 | Received 27 Sep 2018, Accepted 28 Nov 2018, Published online: 07 Dec 2018

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Zsuzsanna Ida Petykó, András Inotai, Anke-Peggy Holtorf, Diana Brixner & Zoltán Kaló. (2020) Barriers and facilitators of exploiting the potential of value-added medicines. Expert Review of Pharmacoeconomics & Outcomes Research 20:3, pages 229-236.
Read now
András Inotai & Zoltán Kaló. (2019) How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 627-632.
Read now

Articles from other publishers (8)

Evelien Moorkens, Teresa Barcina Lacosta, Dalia Dawoud, András Inotai, Manthan Janodia, Chia Jie Tan, Ka Keat Lim, Nishtha Khatri, Catarina Lopes Pereira & Steven Simoens. (2023) A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value in Health 26:8, pages 1137-1144.
Crossref
Conor McCloskey, María Toboso Ortega, Sunita Nair, Maria João Garcia & Federico Manevy. (2022) A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. PharmacoEconomics - Open 7:1, pages 3-36.
Crossref
Eleni Triantafyllidi & John K. Triantafillidis. (2022) Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. Biomedicines 10:8, pages 2045.
Crossref
Enrique Teran, Henry Gomez, Damian Hannois, Mauricio Lema, William Mantilla, Mariana Rico-Restrepo, Elizabeth McElwee, Noe Castro Sanchez, Natalia Valdivieso & Manuel Antonio Espinoza. (2022) Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. The Lancet Oncology 23:7, pages e348-e358.
Crossref
Domenico Tricarico, Anna Sara Convertino, Irsida Mehmeti, Girolamo Ranieri, Francesco Leonetti, Carmelo Laface & Nicola Zizzo. (2022) Inflammatory Related Reactions in Humans and in Canine Breast Cancers, A Spontaneous Animal Model of Disease. Frontiers in Pharmacology 13.
Crossref
Steven Simoens, Arnold G. Vulto & Pieter Dylst. (2021) Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. Pharmaceuticals 14:5, pages 450.
Crossref
Cornelius F. Waller, Julia Möbius & Adolfo Fuentes-Alburo. (2021) Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. British Journal of Cancer 124:8, pages 1346-1352.
Crossref
Tomas Tesar, Peter Golias, Zuzana Kobliskova, Martin Wawruch, Paweł Kawalec & András Inotai. (2020) Potential Cost-Savings From the Use of the Biosimilars in Slovakia. Frontiers in Public Health 8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.